Consumer Health Product Market Fraud During Pandemic Didn’t Surprise US FDA – Woodcock

“This type of activity always emerges during a crisis where people will take advantage of others’ desperation and fear,” says acting Commissioner Janet Woodcock in FDLI conference keynote. Regulated industries’ data are needed to continue responding to COVID-19 and prepare for “what comes next.”

The US Food and Drug Administration's response to the COVID-19 pandemic makes for a long list of topics to discuss. In remarks at a regulatory conference, acting Commissioner Janet Woodcock noted the FDA’s work in the consumer health space near the top.

“The effort by the FDA’s workforce over the past year and a half has been nothing short of monumental,” Woodcock...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation